oncogenic HPV

A human papillomavirus–HPV genotype, especially types 16, 18, but also types 31, 33, and 51, which is pathogenically linked to intraepithelial neoplasia–eg, uterine cervix, termed CIN. See CIN, HPV.

Mentioned in ?

References in periodicals archive ?

The bivalent vaccine protects against HPV-16 and -18, the most common oncogenic HPV types, which are responsible for [approximately equal to]70% of HPV-associated cervical cancers and a large proportion of other HPV-related cancers (1).

Monitoring effect of human papillomavirus vaccines in US population, emerging infections program, 2008-2012

If human papillomavirus vaccines could be delivered as one dose, while retaining their efficacy against the most oncogenic HPV types 16 and 18, we could substantially decrease the global burden of cervical cancer, particularly in resource-poor settings where an annual vaccination program might be difficult to sustain.

Single HPV vaccine dose efficacy similar to 3 doses

GARDASIL 9 was shown to be 97% effective in preventing high-grade lesions of the cervix, vagina and vulva caused by the 5 additional oncogenic HPV types (31, 33, 45, 52, 58).

Sanofi Pasteur MSD : GARDASIL9: New HPV Vaccine Approved in the European Union

9] HPV DNA results were reported as positive for HPV 16, HPV 18 and other high-risk HPV (hrHPV) types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) or negative for oncogenic HPV.

The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa

In conclusion, awareness of the possibility that an oral cavity lesion may represent condyloma acuminatum is important because this lesion is associated with oncogenic HPV genotypes.

Condyloma acuminatum of the buccal mucosa

Palefsky: HPV is by far the most important risk factor, and specifically the oncogenic HPV types.

Tackling tough questions on anal cancer incidence, screening, and HPV vaccination

On August 7, 2013, GSK had submitted a variation to the current Marketing Authorisation to the European Medicines Agency to add administration of the vaccine according to a two-dose schedule (0, 6 months) in girls aged 9 to 14 years old for the prevention of premalignant genital (cervical, vulvar and vaginal) lesions and cervical cancer causally related to certain oncogenic HPV types.

Upcoming Presentations, New Studies, and Stock Price Movements - Research Report on WellPoint, GSK, Forest Laboratories, Intuitive Surgical, and Cubist Pharmaceuticals

While most of the HPV infections disappear naturally, persistent infection with oncogenic HPV will definitely lead to cervical cancer.

Cervical cancer

The presence of oncogenic HPV types confers an elevated risk for the future development of cervical cancer.

Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis

The participants, who at the beginning of the study had a normal Pap test result and were negative for oncogenic HPV, were enrolled in a multi-institutional U.

HIV may not up risk of cervical cancer in women

However, circumcision is associated with a reduced prevalence and persistence of oncogenic HPV infections and circumcised men are also less susceptible to multiple infections.

Global review of age-specific prevalence of HPV in men

In the present retrospective study, we have evaluated the clinical performance of a HPV test by detecting E6/E7 mRNA in 14 oncogenic HPV types from 3-year-old archived PreservCyt samples, all with a cytologic diagnosis of LSIL.

Clinical performance of a human papillomavirus messenger RNA test (aptima HPV assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion

Full browser ?

CITE

Site: Follow: Share:

Open / Close